BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 06, 2007
 |  BioCentury  |  Finance

CV chronicles

CV chronicles

CV chroniclesWith its shares down 62% since it launched angina drug Ranexa ranolazine in March 2006, CV Therapeutics last week asked biotech banker Fred Frank of Lehman to counsel the company on strategic alternatives. A big chunk of the valuation falloff came on March 6, when CVTX slumped 28% on news that Ranexa missed the primary endpoint in the Phase III MERLIN TIMI-36 trial in acute coronary syndrome (ACS). Meanwhile, the drug has not jumped out of the starting blocks in its marketed indication for second-line angina. In its first full quarter on the market (2Q06),...

Read the full 468 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >